STORM Therapeutics Announces Appointments to Scientific Advisory Board

11 December 2017, Cambridge, UK: STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of both Professor Mark Dawson and Dr Paul Leeson to the Scientific Advisory Board.

Professor Mark Dawson is a clinician-scientist in the Sir Peter MacCallum Department of Oncology and Centre of Cancer Research at the University of Melbourne and has extensive experience in epigenetics, having spent many years researching epigenetic regulation of leukaemia stem cells. Mark’s research identified a new therapeutic strategy for acute myeloid leukaemia by targeting the BET bromodomain proteins that function as epigenetic readers, and helped set the platform for clinical trials with this first in class epigenetic therapy.

Dr Paul Leeson is a medicinal chemist with more than35 years’ experience of drug discovery and development in senior roles in several major pharmaceutical companies including Smith Kline and French, Merck Sharp and Dohme, Wyeth (USA), AstraZeneca, and GlaxoSmithKline.

These appointments will strengthen STORM’s advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.

To continue reading the press release please click here

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...